title: Effects of ranolazine on left ventricular diastolic and systolic function in patients with chronic coronary disease and stable angina.
abstract: BACKGROUND
  The present study examined the effect of ranolazine, which acts via the mechanism of selective inhibition of late INa+, on parameters of left ventricular systolic and diastolic function in patients suffering from angiographically confirmed chronic coronary artery disease, presenting with chronic stable angina.
  
  
  METHODS
  We studied 40 patients (age 67 ± 9 years; 30 men, 10 women) with chronic coronary artery disease who reported angina symptoms on optimal medication and who were not suitable for invasive treatment. Patients were randomized to the ranolazine group (group A, 20 patients taking oral ranolazine 500 mg bid for 3 months) and the control group (group B, 20 patients who did not receive the drug). Left ventricular systolic and diastolic function was assessed echocardiographically at baseline and after the end of the three-month treatment period. Left ventricular ejection fraction by the modified Simpson's method, E and A left ventricular filling velocities, E/A ratio, deceleration time (DT) of E, isovolumic relaxation time (IVRT), E and A waves, and the E/E ratio were measured using 2-dimensional echocardiography, Doppler and tissue Doppler imaging (TDI).
  
  
  RESULTS
  Group A patients demonstrated a clear improvement of their initial angina symptoms. There were no adverse effects from ranolazine requiring withdrawal from the study. There was no statistically significant change in left ventricular systolic function in either group. A statistically significant change was seen in indexes of diastolic function measured using both conventional Doppler and TDI in Group A patients compared with Group B patients after three months' ranolazine treatment period. The changes in left ventricular diastolic function indexes in Group A patients were as follows: E 0.58 ± 0.11 vs. 0.76 ± 0.12 m/s, p<0.001; A 0.71 ± 0.22 vs. 0.83 ± 0.19 m/s, p<0.001; E/A 0.81 ± 0.14 vs. 0.97 ± 0.17, p<0.005; 5.4 ± 0.7 vs. 6.8 ± 0.9 cm/s, p<0.005; 7.2 ± 0.8 vs. 8.3 ± 1.1 cm/s, p<0.005; E/ 10.7 ± 1.1 vs. 11.1 ± 0.8, p=ns; DT 251 ± 14 vs. 226 ± 17 ms, p<0.004; IVRT 95 ± 11 vs. 74 ± 9 ms, p<0.001. Systolic function did not change: EF 46.3 ± 3.4 vs. 46.7 ± 2.7%, p: ns.
  
  
  CONCLUSIONS
  The use of ranolazine in patients suffering from chronic coronary artery disease has a favorable impact on diastolic function parameters. Accordingly, a clinical benefit could be observed due to an improvement in patients' symptoms.
authors.affiliation: Cardiology Department, KAT General Hospital of Athens, Greece.
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Babalis
authors.forename: Vlassis
authors.initials: V
authors.lastname: Tritakis
authors.forename: Georgios
authors.initials: G
authors.lastname: Floros
authors.forename: Aggeliki
authors.initials: A
authors.lastname: Mouzarou
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Kafkas
authors.forename: Konstantina
authors.initials: K
authors.lastname: Bampali
authors.forename: Georgios
authors.initials: G
authors.lastname: Mertzanos
mesh_terms: D000368:Aged; D060050:Angina, Stable / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D018619:Echocardiography, Doppler, Pulsed / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069458:Ranolazine / Q000008:administration & dosage* / Q000009:adverse effects; D026941:Sodium Channel Blockers / Q000008:administration & dosage* / Q000009:adverse effects; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology
chemical_list: D026941:Sodium Channel Blockers; D000069458:Ranolazine